Skip to main content
. 2020 Sep 1;12(9):2471. doi: 10.3390/cancers12092471

Figure 2.

Figure 2

Strategies for improving clinical curative effects of CIK cells. PBMCs are isolated by density gradient centrifugation and expended with IFN-γ, anti-CD3 and IL-2. After 14–21 days, CIK cells are infused into the patient. The anti-tumor activity of CIK cells can be enhanced by adding cytokines like IL-18 or RetroNectin during expansion. DCs have high ability to present tumor antigens and compensate the lack of tumor antigen specificity of CIK cells. Targeted agents such as sunitinib and sorafenib or immune checkpoint inhibitor anti-PD-1 antibodies also have a synergistic effect with CIK cells. CIK cell, cytokine-induced killer cell; PBMC, peripheral blood mononuclear cell; IFN-γ, interferon-γ; IL-2, interleukin-2; IL-18, interleukin-18; VEGFR, vascular endothelial growth factor receptor; PD-1, programmed cell death-1; DC, dendritic cell; RBC, red blood cell.